Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer ' s disease

被引:0
|
作者
Wise-Brown, Alexandria [1 ]
Brangman, Sharon A. [2 ]
Henderson, J. Neil [3 ]
Willis-Parker, Monica [4 ]
Monroe, Stephanie [5 ,6 ]
Mintzer, Jacobo E. [7 ]
Grundman, Michael [8 ,9 ]
Smith, Janice [10 ]
Doody, Rachelle S. [1 ,11 ]
Lin, Helen [1 ]
Assman, Beverly [1 ]
Rippon, Gregory A. [1 ]
Gonzales, Rozanno [1 ]
Assuncao, Sheila Seleri [1 ]
机构
[1] US Med Affairs, Gentech Inc, South San Francisco, CA 94080 USA
[2] SUNY Upstate Med Univ, Dept Geriatr, Syracuse, NY USA
[3] Univ Minnesota, Dept Family Med & Biobehav Hlth, Duluth, MN USA
[4] Emory Univ, Sch Med, Goizueta Alzheimers Dis Res Ctr, Atlanta, GA 30307 USA
[5] Minor Engagement Core, Atlanta, GA USA
[6] UsAgainstAlzheimers, Ctr Brain Hlth Equ, Washington, DC USA
[7] Med Univ South Carolina, Dept Hlth Studies, Charleston, SC USA
[8] Global R&D Partners LLC, San Diego, CA USA
[9] Univ Calif San Diego, Dept Neurosci, San Diego, CA USA
[10] Roche Prod Ltd, Welwyn Garden City, England
[11] F Hoffmann La Roche Ltd, Basel, Switzerland
关键词
Clinical trial protocol; Diversity; Equity; Inclusion; Underrepresentation; Alzheimer ' s disease; Social determinants of health; STRATEGIES;
D O I
10.1016/j.eclinm.2024.102693
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clinical trial participation across disease areas, including Alzheimer ' s disease (AD), has been biased towards White participants of European ancestry. To support clinical decision-making across diverse populations, we must recognize and address barriers to trial participation. To inform the design of ALUMNI AD, a trial focused on historically underrepresented AD populations, we held advice-seeking fora with key stakeholders to understand barriers and identify potential solutions to maximize trial participation of underrepresented racial and ethnic groups in the US. Strategies identi fi ed from this process include: obtaining and implementing recommendations from community stakeholders; establishing a simple and inclusive prescreening and screening process; supporting participants and care partners; identifying and activating community-centric clinical sites; and demonstrating community commitment. While ALUMNI AD did not commence, we hope that our insights could be incorporated into future studies to improve diversity, equity, and inclusion in AD clinical research.
引用
收藏
页数:8
相关论文
共 39 条
  • [21] Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer′s Disease Study (LEADS)
    Cho, Hanna
    Mundada, Nidhi S.
    Apostolova, Liana G.
    Carrillo, Maria C.
    Shankar, Ranjani
    Amuiri, Alinda N.
    Zeltzer, Ehud
    Windon, Charles C.
    Soleimani-Meigooni, David N.
    Tanner, Jeremy A.
    Heath, Courtney Lawhn
    Lesman-Segev, Orit H.
    Aisen, Paul
    Eloyan, Ani
    Lee, Hye Sun
    Hammers, Dustin B.
    Kirby, Kala
    Dage, Jeffrey L.
    Fagan, Anne
    Foroud, Tatiana
    Grinberg, Lea T.
    Jack, Clifford R.
    Kramer, Joel
    Kukull, Walter A.
    Murray, Melissa E.
    Nudelman, Kelly
    Toga, Arthur
    Vemuri, Prashanthi
    Atri, Alireza
    Day, Gregory S.
    Duara, Ranjan
    Graff-Radford, Neill R.
    Honig, Lawrence S.
    Jones, David T.
    Masdeu, Joseph
    Mendez, Mario
    Musiek, Erik
    Onyike, Chiadi U.
    Riddle, Meghan
    Rogalski, Emily J.
    Salloway, Stephen
    Sha, Sharon
    Turner, Raymond Scott
    Wingo, Thomas S.
    Wolk, David A.
    Koeppe, Robert
    Iaccarino, Leonardo
    Dickerson, Bradford C.
    La Joie, Renaud
    Rabinovici, Gil D.
    ALZHEIMERS & DEMENTIA, 2023, 19 : S98 - S114
  • [22] Sociodemographic and Clinical Insights into Behavioral Variant Frontotemporal Dementia and Early-Onset Alzheimer's Disease in Colombia: A Comprehensive Study of Patients and Caregivers
    Zapata-Restrepo, Lina M.
    Possin, Katherine
    Allen, Isabel E.
    Rivas, Juan C.
    Dorado, Carlos A.
    Miranda, Carlos
    Cardozo, Maria Mercedes
    Ibanez, Agustin
    INTERNATIONAL PSYCHOGERIATRICS, 2024, 36 : 115 - 115
  • [23] Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials
    Kumar Kandadi Muralidharan
    Kenneth G. Kowalski
    Xiao Tong
    Samantha Budd Haeberlein
    Rajasimhan Rajagovindan
    Ivan Nestoro
    Journal of Pharmacokinetics and Pharmacodynamics, 2023, 50 : 145 - 145
  • [24] A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes
    Wang, Xin
    Broce, Iris
    Qiu, Yuqi
    Deters, Kacie D.
    Fan, Chun Chieh
    Dale, Anders M.
    Edland, Steven D.
    Banks, Sarah J.
    ALZHEIMERS & DEMENTIA, 2023, 19 (07) : 3078 - 3086
  • [25] Patient dependence and clinical measures of cognitive impairment, functional disability and behaviour in Alzheimer's disease: results from dependence in AD in England (DADE) study
    Jones, R. W.
    Lacey, L.
    Knapp, M.
    Romeo, R.
    Sato, A.
    Niecko, T.
    Trigg, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 118 - 118
  • [26] Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials
    Muralidharan, Kumar Kandadi
    Kowalski, Kenneth G. G.
    Tong, Xiao
    Haeberlein, Samantha Budd
    Rajagovindan, Rajasimhan
    Nestorov, Ivan
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2023, 50 (01) : 45 - 62
  • [27] The Proteome Profile of Olfactory Ecto-Mesenchymal Stem Cells-Derived from Patients with Familial Alzheimer's Disease Reveals New Insights for AD Study
    Rochin-Hernandez, Lory J.
    Jimenez-Acosta, Miguel A.
    Ramirez-Reyes, Lorena
    Figueroa-Corona, Maria del Pilar
    Sanchez-Gonzalez, Victor J.
    Orozco-Barajas, Maribel
    Meraz-Rios, Marco A.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
  • [28] Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil
    Levine, Stephen Z.
    Goldberg, Yair
    Yoshida, Kazufumi
    Samara, Myrto
    Cipriani, Andrea
    Iwatsubo, Takeshi
    Leucht, Stefan
    Furukawa, Toshiaki A.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2022, 148 : 159 - 164
  • [29] The congruency of neuropsychological and F18-FDG brain PET/CT diagnostics of Alzheimer's Disease (AD) in routine clinical practice: insights from a mixed neurological patient cohort
    Hansen, Sascha
    Keune, Jana
    Kuefner, Kim
    Meister, Regina
    Habich, Juliane
    Koska, Julia
    Forster, Stefan
    Oschmann, Patrick
    Keune, Philipp M.
    BMC NEUROLOGY, 2022, 22 (01)
  • [30] The congruency of neuropsychological and F18-FDG brain PET/CT diagnostics of Alzheimer’s Disease (AD) in routine clinical practice: insights from a mixed neurological patient cohort
    Sascha Hansen
    Jana Keune
    Kim Küfner
    Regina Meister
    Juliane Habich
    Julia Koska
    Stefan Förster
    Patrick Oschmann
    Philipp M. Keune
    BMC Neurology, 22